Natasha O Moraka1, Sikhulile Moyo1,2, Gloria Mayondi1, Jean Leidner3, Maryanne Ibrahim4, Christiana Smith5, Adriana Weinberg5, Shaobing Li5, Prisca K Thami1, Betsy Kammerer6,7, Gbolahan Ajibola1, Rosemary Musonda1,2, Roger Shapiro1,2,7,8, Simani Gaseitsiwe1,2, Shahin Lockman1,2,7,9. 1. Research Laboratory, Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana. 2. Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA. 3. Goodtables Data Consulting, Norman, OK. 4. Department of Pediatrics, Baylor College of Medicine, Houston, TX. 5. Pediatric Infectious Diseases University of Colorado Denver, Denver, CO. 6. Department of Psychiatry, Boston Children's Hospital, Boston, MA. 7. Harvard Medical School, Boston, MA. 8. Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, MA. 9. Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA.
Abstract
BACKGROUND: We evaluated the association between maternal cytomegalovirus (CMV) viremia during pregnancy and adverse birth and infant health outcomes in HIV-infected mothers and their HIV-exposed uninfected infants. METHODS: HIV-positive women and their infants were followed prospectively from pregnancy through 2 years postpartum in the "Tshipidi" study in Botswana. We analyzed the association between detectable CMV DNA in maternal blood at delivery and adverse birth outcomes (stillbirth, preterm delivery, small for gestational age, or birth defect), as well as infant hospitalization and mortality through 24 months. RESULTS: We measured CMV DNA in blood samples from 350 (77.1%) of 454 HIV-positive women from the Tshipidi study. The median maternal CD4 count was 422 cells/mL, and median HIV-1 RNA at entry was 3.2 log10 copies/mL. Fifty-one (14.6%) women had detectable CMV DNA. In unadjusted analyses, detectable CMV DNA was associated with higher maternal HIV-1 RNA [odds ratio (OR) 1.4, 95% confidence interval (CI): 1.1 to 1.9], presence of a birth defect (OR 9.8, 95% CI: 1.6 to 60.3), and occurrence of any adverse birth outcome (OR 2.0, 95% CI: 1.04 to 3.95). In multivariable analysis, we observed a trend toward association between detectable maternal CMV DNA and occurrence of any adverse birth outcome (adjusted OR 1.9, 95% CI: 0.96 to 3.8). Maternal CMV viremia was not associated with infant hospitalization and/or death by 24 months. CONCLUSIONS: Approximately 1 in 6 HIV-positive women in Botswana had detectable CMV DNA in blood at delivery. The presence of maternal CMV viremia had a borderline association with adverse birth outcomes but not with 24-month morbidity or mortality in HIV-exposed uninfected children.
BACKGROUND: We evaluated the association between maternal cytomegalovirus (CMV) viremia during pregnancy and adverse birth and infant health outcomes in HIV-infected mothers and their HIV-exposed uninfected infants. METHODS: HIV-positive women and their infants were followed prospectively from pregnancy through 2 years postpartum in the "Tshipidi" study in Botswana. We analyzed the association between detectable CMV DNA in maternal blood at delivery and adverse birth outcomes (stillbirth, preterm delivery, small for gestational age, or birth defect), as well as infant hospitalization and mortality through 24 months. RESULTS: We measured CMV DNA in blood samples from 350 (77.1%) of 454 HIV-positive women from the Tshipidi study. The median maternal CD4 count was 422 cells/mL, and median HIV-1 RNA at entry was 3.2 log10 copies/mL. Fifty-one (14.6%) women had detectable CMV DNA. In unadjusted analyses, detectable CMV DNA was associated with higher maternal HIV-1 RNA [odds ratio (OR) 1.4, 95% confidence interval (CI): 1.1 to 1.9], presence of a birth defect (OR 9.8, 95% CI: 1.6 to 60.3), and occurrence of any adverse birth outcome (OR 2.0, 95% CI: 1.04 to 3.95). In multivariable analysis, we observed a trend toward association between detectable maternal CMV DNA and occurrence of any adverse birth outcome (adjusted OR 1.9, 95% CI: 0.96 to 3.8). Maternal CMV viremia was not associated with infant hospitalization and/or death by 24 months. CONCLUSIONS: Approximately 1 in 6 HIV-positive women in Botswana had detectable CMV DNA in blood at delivery. The presence of maternal CMV viremia had a borderline association with adverse birth outcomes but not with 24-month morbidity or mortality in HIV-exposed uninfected children.
Authors: Elaine L Duryea; Pablo J Sánchez; Jeanne S Sheffield; Gregory L Jackson; George D Wendel; Barbara S McElwee; Linda F Boney; Mary M Mallory; Kristine E Owen; Elizabeth K Stehel Journal: Pediatr Infect Dis J Date: 2010-10 Impact factor: 2.129
Authors: M Floridia; M F Pirillo; A Degli Antoni; A Molinari; E Tamburrini; C Pinnetti; G Guaraldi; G Nardini; G Masuelli; S Dalzero; I Cetin; M Sansone; R Amici; M Ravizza Journal: Clin Microbiol Infect Date: 2016-07-09 Impact factor: 8.067
Authors: Peter W Hunt; Jeffrey N Martin; Elizabeth Sinclair; Lorrie Epling; Juli Teague; Mark A Jacobson; Russell P Tracy; Lawrence Corey; Steven G Deeks Journal: J Infect Dis Date: 2011-05-15 Impact factor: 5.226
Authors: Toni Frederick; James Homans; LaShonda Spencer; Francoise Kramer; Alice Stek; Eva Operskalski; Andrea Kovacs Journal: Clin Infect Dis Date: 2012-06-06 Impact factor: 9.079
Authors: Jennifer A Slyker; Barbara L Lohman-Payne; Sarah L Rowland-Jones; Phelgona Otieno; Elizabeth Maleche-Obimbo; Barbra Richardson; Carey Farquhar; Dorothy Mbori-Ngacha; Vincent C Emery; Grace C John-Stewart Journal: AIDS Date: 2009-01-02 Impact factor: 4.177
Authors: Charlotte-Eve S Short; Rachael A Quinlan; Xuan Wang; Veronica Georgiana Preda; Ann Smith; Julian R Marchesi; Yooni S Lee; David A MacIntyre; Phillip R Bennett; Graham P Taylor Journal: Front Cell Infect Microbiol Date: 2021-11-29 Impact factor: 5.293